文献速递前列腺癌

低危前列腺癌主动监测患者中广泛经直肠重复活检加前部取样的价值:瑞典主动监测随机研究(SAMS)的比较

The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS).
PubMed 文献 · Eur Urol · 2019-03-14

这项随机多中心试验纳入340名新诊断低体积Gleason分级组1前列腺癌的瑞典男性(40-75岁),比较广泛经直肠活检加前部取样(中位19针)与标准经直肠活检(中位12针)。广泛活检组Gleason分级组≥2癌检出率为16%(156例中),标准活检组为10%(164例中),差异5.7%(95%CI -0.2%至13%,p=0.09)。前列腺特异性抗原密度与前部定向活检针芯中癌检出呈强线性关联。试验不支持广泛经直肠重复活检模板的普遍使用,但前部定向针芯中癌常见,尤其在高PSA密度男性中。

要点

  • 广泛活检组Gleason分级组≥2癌检出16%,标准活检组10%,差异未达统计学显著(p=0.09)。
  • PSA密度每增加0.1-ng/ml/cm3,前部定向针芯任何癌的OR为2.2(95%CI 1.3-3.9,p=0.004)。
  • PSA密度每增加0.1-ng/ml/cm3,前部定向针芯Gleason分级组≥2癌的OR为2.3(95%CI 1.2-4.4,p=0.015)。

核心结论

  • 试验不支持广泛经直肠重复活检模板的普遍使用,但前部定向针芯中癌常见,尤其在高PSA密度男性中。
  • PSA密度越高,在系统重复活检中包含前部取样的理由越强。

研究设计与样本

  • 随机多中心试验,2012至2016年纳入340名瑞典男性,年龄40-75岁,新诊断低体积Gleason分级组1前列腺癌。
  • 干预为广泛经直肠活检加前部取样(中位19针)或标准经直肠活检(中位12针)。
  • 主要结局为Gleason分级组≥2癌;次要结局为前部定向活检针芯中癌和活检后感染。

主要发现

  • 广泛活检组156例中16%检出Gleason分级组≥2癌,标准活检组164例中10%检出,差异5.7%(95%CI -0.2%至13%,p=0.09)。
  • 前部定向针芯任何癌的OR为2.2(95%CI 1.3-3.9,p=0.004),Gleason分级组≥2癌的OR为2.3(95%CI 1.2-4.4,p=0.015),均按PSA密度每0.1-ng/ml/cm3增量计算。
  • 活检后感染在两组中同样常见。

关键数值与推荐

  • 广泛经直肠活检加前部取样中位19针,标准经直肠活检中位12针。
  • PSA密度每增加0.1-ng/ml/cm3,前部定向针芯任何癌OR 2.2(95%CI 1.3-3.9,p=0.004)。
  • PSA密度每增加0.1-ng/ml/cm3,前部定向针芯Gleason分级组≥2癌OR 2.3(95%CI 1.2-4.4,p=0.015)。

临床怎么用

  • 试验不支持广泛经直肠重复活检模板的普遍使用。
  • PSA密度越高,在系统重复活检中包含前部取样的理由越强。

局限性

  • 未使用磁共振成像。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A systematic repeat biopsy is recommended for men starting on active surveillance for prostate cancer, but the optimal number and distribution of cores are unknown. OBJECTIVE: To evaluate an extensive repeat transrectal biopsy with anterior sampling in men starting on active surveillance. DESIGN, SETTING, AND PARTICIPANTS: Randomised multicentre trial. From 2012 to 2016, 340 Swedish men, aged 40-75yr, with recently diagnosed low-volume Gleason grade group 1 prostate cancer were included. INTERVENTION: Either an extensive transrectal biopsy with anterior sampling (median 19 cores) or a standard transrectal biopsy (median 12 cores). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Primary outcome measure: Gleason grade group ≥2 cancer. SECONDARY OUTCOMES: Cancer in anteriorly directed biopsy cores and postbiopsy infection. Nonparametric statistical tests were applied. RESULTS AND LIMITATIONS: Gleason grade group ≥2 cancer was detected in 16% of 156 men who had an extensive biopsy and in 10% of 164 men who had a standard biopsy, a 5.7% difference (95% confidence interval [CI]-0.2% to 13%, p=0.09). There was a strong linear association between prostate-specific antigen (PSA) density and cancer in the anteriorly directed biopsy cores. The odds ratios for cancer in the anteriorly directed cores were for any cancer 2.2 (95% CI 1.3-3.9, p=0.004) and for Gleason grade group ≥2 cancer 2.3 (95% CI 1.2-4.4, p=0.015) per 0.1-ng/ml/cm3 increments. Postbiopsy infections were equally common in the two groups. A limitation is that magnetic resonance imaging was not used. CONCLUSIONS: The trial did not support general use of the extensive transrectal repeat biopsy template, but cancer in the anteriorly directed cores was common, particularly in men with high PSA density. The higher the PSA density, the stronger the reason to include anterior sampling at a systematic repeat biopsy. PATIENT SUMMARY: This trial compared two different templates for transrectal prostate biopsy in men starting on active surveillance for low-risk prostate cancer. Cancer was often found in the front part of the prostate, which is not sampled on a standard prostate biopsy.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Bratt O, Holmberg E, Andrén O, et al. The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS). Eur Urol. 2019. PMID: 30878303. doi:10.1016/j.eururo.2019.02.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。